Abstract
The invention relates to a nucleic acid apatamer with the capability of binding specifically to and inhibiting TLR-4, to a complex comprising said aptamer and a functional group, as well as to pharmaceutical compositions thereof. The invention also relates to uses and methods for detecting TLR-4 and to uses and methods for inhibiting TLR-4. Finally, the invention also relates to an aptamer for use in manufacturing a drug for the treatment of a pathology characterized by an increase in expression of TLR4 and/or an increase in activation of TIR-4.
Full Text
What is claimed is:
The invention relates to a nucleic acid apatamer with the capability of binding specifically to and inhibiting TLR-4, to a complex comprising said aptamer and a functional group, as well as to pharmaceutical compositions thereof. The invention also relates to uses and methods for detecting TLR-4 and to uses and methods for inhibiting TLR-4. Finally, the invention also relates to an aptamer for use in manufacturing a drug for the treatment of a pathology characterized by an increase in expression of TLR4 and/or an increase in activation of TIR-4.
Timeline
Filed
04/14/2026Published
07/30/2026Granted
Not AvailableIPC Codes(3)
C12N 15/115:Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
A61K 31/7088:Compounds having three or more nucleosides or nucleotides
G01N 33/566:using specific carrier or receptor proteins as ligand binding reagent